By Professor Michael Leonard Friedlander

Conference Papers

Butow P; Price M; Bell M; Webb P; deFazio A; Friedlander M, 2013, 'CARING FOR WOMEN WITH OVARIAN CANCER IN THE LAST YEAR OF THEIR LIFE: IMPACT ON THE CAREGIVER', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 103 - 103, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800141&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Mizrahi D; Naumann F; Broderick C; Yip D; Davis A; Samara J; Ryan M; Friedlander M, 2013, 'PHYSICAL ACTIVITY (PA) PARTICIPATION FOR WOMEN WITH OVARIAN CANCER', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 114 - 114, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800170&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Price M; Butow P; Bell M; Friedlander M; deFazio A; Webb P, 2013, 'Psychosocial Predictors of Survival in Invasive Ovarian Cancer: A Population-Based Prospective Study', in PSYCHO-ONCOLOGY, WILEY-BLACKWELL, pp. 46 - 47, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325687200070&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Sousa M; Meiser B; Hickey M; Jarvis S; Peatte M; Lewis C; Friedlander M, 2013, 'QUALITATIVE ANALYSIS OF KNOWLEDGE, ATTITUDES AND EXPERIENCES REGARDING URINARY SYMPTOMS AMONG POSTMENOPAUSAL WOMEN TAKING AROMATASE INHIBITORS FOR EARLY STAGE BREAST CANCER', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 143 - 143, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800262&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Butow P; Price M; Bell M; Fardell J; Aldridge L; McGowan N; Fazio A; Friedlander M; Webb P, 2013, 'Quality of Life, Distress and Coping in Women With Ovarian Cancer: A Population Based, Longitudinal Study', in PSYCHO-ONCOLOGY, WILEY-BLACKWELL, pp. 44 - 44, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325687200066&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

King MT; Freudensprung U; Stockler M; Friedlander M; Lee C; Sneller V; Hilpert F; Pujade-Lauraine E; Wenzel L, 2013, 'Analyzing patient-reported outcome (PRO) endpoints in advanced cancer clinical trials: responder analysis versus mixed model for repeated measures (MMRM) illustrated with results from the AURELIA ovarian cancer trial', in QUALITY OF LIFE RESEARCH, SPRINGER, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000209359000043&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Campbell I; Hunter S; Mathew W; Antill Y; Bae S; Ananda S; Topp M; Lipton L; Liauw W; Jobling T; Boussioutas A; Christie M; Allan P; Friedlander M; Fox S; Defazio A; Bowtell D; Pyman J; Scott C; Gorringe K, 2013, 'Mucinous ovarian tumors: Are they all the same?', in CLINICAL CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/1078-0432.OVCA13-A3

Mizrahi D; Naumann F; Broderick C; Ryan M; Friedlander M, 2013, 'PHYSICAL ACTIVITY AND SLEEP DISTURBANCES FOR WOMEN WITH RECURRENT OVARIAN CANCER UNDERGOING CHEMOTHERAPY', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000330379502010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

del Campo JM; Kurzeder C; Berton-Rigaud D; Kim BG; Friedlander M; Zamagni C; Sakuragi N; Canzler U; Crescenzo RJ; du Bois A, 2013, 'PROGRESSION-FREE SURVIVAL BY GCIG CRITERIA: ANALYSIS OF THE SECONDARY ENDPOINT OF THE AGO-OVAR16 TRIAL', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000330379500111&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Mateo J; Friedlander M; Sessa C; Leunen K; Nicum S; Gourley C; Fielding A; Bowen K; Kaye S; Molife LR, 2013, 'Administration of continuous/intermittent olaparib in ovarian cancer patients with a germline BRCA1/2 mutation to determine an optimal dosing schedule for the tablet formulation', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, NETHERLANDS, Amsterdam, pp. S161 - S161, presented at European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, NETHERLANDS, Amsterdam, 27 September 2013 - 01 October 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000326843601074&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Oza AM; Cibula D; Oaknin Benzaquen A; Poole CJ; Mathijssen RHJ; Sonke GS; Mackay H; Lowe ES; Read J; Friedlander M, 2013, 'Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): BRCA1/2 mutation (BRCAm) and interim overall survival analyses', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, NETHERLANDS, Amsterdam, pp. S712 - S713, presented at European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, NETHERLANDS, Amsterdam, 27 September 2013 - 01 October 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000326843604308&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Friedlander M; Knoll S; Meier W; Lesoin A; Kim JW; Poveda A; Buck M; Scambia G; Shimada M; Du Bois A, 2013, 'Quality of life in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC) receiving either pazopanib monotherapy or placebo after first-line chemotherapy: AGO-OVAR16 results', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, NETHERLANDS, Amsterdam, pp. S713 - S713, presented at European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, NETHERLANDS, Amsterdam, 27 September 2013 - 01 October 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000326843604309&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Collins I; Milne RL; McLachlan SA; Friedlander M; Hickey M; Weideman P; Birch KE; Hopper JL; Phillips K-A, 2013, 'DO BRCA1 AND BRCA2 MUTATION CARRIERS HAVE EARLIER NATURAL MENOPAUSE THAN THEIR NON-CARRIER RELATIVES?', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 54 - 54, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000329462300026&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Gorringe K; Hunter S; Wakefield MJ; Antill Y; Ryland G; Bae S; Topp M; Lipton L; Liauw W; Jobling T; Boussioutas A; Christie M; Friedlander M; Fox S; DeFazio A; Bowtell D; Pyman J; Scott CL; Campbell I, 2013, 'MUCINOUS OVARIAN TUMOURS: IS ONE OF THESE THINGS NOT LIKE THE OTHERS?', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 45 - 46, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000329462300010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Collins I; Milne RL; Weideman P; McLachlan SA; Friedlander M; Hopper JL; Phillips K-A, 2013, 'RISK-REDUCING BEHAVIOUR OF FEMALE BRCA1 AND BRCA2 MUTATION CARRIERS; LONG-TERM FOLLOW-UP OF PARTICIPANTS IN kConFab', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 45 - 45, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000329462300008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Stockler MR; Hilpert F; Friedlander M; King M; Wenzel LB; Lee C; Joly F; De Gregorio N; Arija JAA; Mirza MR; Sorio R; Freudensprung U; Sneller V; Hales G; lauraine EP, 2013, 'Health-related quality of life (HRQoL) results from the AURELIA trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (OC)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419602056&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin GJS; Scott CL; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Macpherson E; Dougherty B; Juergensmeier JM; Orr M; Matulonis U, 2013, 'Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419602019&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Kaufman B; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmana J; Mitchell G; Fried G; Bowen K; Fielding A; Domchek SM, 2013, 'Olaparib monotherapy in patients with advanced cancer and a germ-line BRAC1/2 mutation: An open-label phase II study', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419600435&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Friedlander M; Sjoquist KM; Sommeijer DW; Bailey L; Marlyn J; Gillies K; Mileshkin LR; O'Connel R; Gebski V; Vaughan MM; Blomtield P; Beale PJ; Quinn M; Stockier MR; Lombard JM; Hadley AM; Amant F; Edmondson RJ, 2013, 'PARAGON: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynecologic neoplasms: ANZGOG 0903.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419605470&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Du Bois A; Floquet A; Kim JW; Rau J; Del Campo JM; Friedlander M; Pignata S; Fujiwara K; Vergote I; Colombo N; Mirza MR; Monk BJ; Wimberger P; Ray-Coquard I; Zang R; Diaz-Padilla I; Baumann KH; Kim JH; Harter P, 2013, 'Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer (AOC): Results of an international intergroup trial (AGO-OVAR16).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419605347&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Du Bois A; Floquet A; Kim JW; Rau J; Maria Del Campo J; Friedlander M; Pignata S; Fujiwara K; Vergote I; Colombo N; Mirza MR; Monk BJ; Wimberger P; Ray-Coquard I; Zang R; Diaz-Padilla I; Baumann KH; Kim JH; Harter P, 2013, 'Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, http://dx.doi.org/10.1200/jco.2013.31.18_suppl.lba5503

Isakoff SJ; Pulhalla S; Shepherd SP; Falotico N; Kaufman B; Friedlander M; Robson M; Domchek S; Garber J; McKeegan E; Chyla B; Qian J; Giranda VL, 2012, 'A randomized, phase 2 study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with temozolomide (TMZ) or in combination with carboplatin (C) and paclitaxel (P) versus placebo plus C/P in subjects with BRCA1 or BRACA2 mutation and metastatic breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/0008-5472.SABCS12-OT2-3-07

Collins IM; Milne RL; McLachlan SA; Friedlander M; Birch KE; Weideman PC; Hopper JL; Phillips K-A, 2012, 'Do BRCA1 and BRCA2 mutation carriers have an earlier natural menopause than their non-carrier relatives: A study from the Kathleen Cuningham Foundation Consortium For Research Into Familial Breast Cancer (kConFab).', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/0008-5472.SABCS12-P4-13-10

Mercieca-Bebber RL; Butow PN; Friedlander M; King MT, 2012, 'OVARIAN CANCER PATIENTS' EXPECTATIONS OF PALLIATIVE CHEMOTHERAPY: THE FINE LINE BETWEEN HOPE AND MISUNDERSTANDING', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 244 - 244, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000310544400075&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Sommeijer DW; Price MA; Bell M; Friedlander M; Stockler M; Defazio A; Webb PM; Butow PN, 2012, 'QUALITY OF LIFE AND COPING IN OVARIAN CANCER: THE LAST YEAR OF LIFE', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 355 - 355, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000310544400415&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Mileshkin LR; Narayan K; Moore KN; Rischin D; Trimble EL; Stockler MR; King M; Kolodziej I; Martyn J; Friedlander M; Quinn M; Shrivastava SK; Small W; Thomas G; Craighead PS; Gebski V, 2012, 'A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The OUTBACK TRIAL.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2012 - 06 June 2012, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318009803669&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Grimison PS; Chatfield MD; Mazhar D; Toner GC; Chester JD; Stockler MR; Stark DP; Thomson DB; Shamash J; Friedlander M; White J; Gebski V; Wason J; Boland AL; Rimmer YL; McDonald A; Gurney H; Rosenthal M; Singhal N; Williams MV, 2012, 'Accelerated BEP for metastatic germ cell tumors: Combined analysis of Australian and UK phase I/II trials', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2012 - 06 June 2012, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318009802677&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Oza AM; Cibula D; Oaknin A; Poole CJ; Mathijssen RHJ; Sonke GS; Colombo N; Spacek J; Vuylsteke P; Hirte HW; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Tchakov I; Friedlander M, 2012, 'Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2012 - 06 June 2012, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318009803631&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Bennett BK; Lloyd AR; Webber K; Friedlander M; Goldstein D, 2012, 'Predictors of resilience in women treated for breast cancer: A prospective study', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2012 - 06 June 2012, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318009802389&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Sjoquist KM; Lee C; Lord S; Chatfield MD; Friedlander M; Simes J; Marschner I, 2012, 'Progression-free survival (PFS) as a surrogate end point for overall survival (OS) in first-line treatment of advanced epithelial ovarian cancer (EOC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2012 - 06 June 2012, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318009803651&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Molife LR; Mateo J; McGoldrick T; Krebs M; Drew Y; Banerjee SN; Nicum S; Ranson M; Rustin GJS; Sessa C; Plummer R; Leunen K; Friedlander M; Swaisland H; Burke W; McCormack P; Pemberton K; Tchakov I; Kaye SB; Gourley C, 2012, 'Safety and efficacy results from two randomized expansions of a phase I study of a tablet formulation of the PARP inhibitor, olaparib, in ovarian and breast cancer patients with BRCA1/2 mutations', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2012 - 06 June 2012, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318009802292&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Ang JE; Gourley C; High HA; Shapira-Frommer R; Powell CB; Castonguay V; De Greve J; Yap TA; Fong PCC; Olmos D; Banerjee SN; Chen L-M; Friedlander M; Kaufman B; Oza AM; De Bono JS; Gore ME; Kaye SB, 2012, 'Use of chemotherapy (CT) in BRCA1/2-deficient ovarian cancer (BDOC) patients (pts) with poly-ADP-ribose polymerase inhibitor (PARPi) resistance: A multi-institutional study', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2012 - 06 June 2012, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318009803479&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Park SB; Lin CSY; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC, 2011, 'A Novel Approach to the Emerging and Frequent Problem of Sustained Long-term Oxaliplatin-induced Neurotoxicity', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, SWEDEN, Stockholm, pp. S436 - S436, presented at European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, SWEDEN, Stockholm, 23 September 2011 - 27 September 2011, http://dx.doi.org/10.1016/S0959-8049(11)71792-0

Bennett BK; Goldstein D; Friedlander M; Park SB; Kiernan MG, 2011, 'Oxaliplatin-induced Neurotoxicity - Comparing Four Methods of Assessment', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, SWEDEN, Stockholm, pp. S234 - S234, presented at European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, SWEDEN, Stockholm, 23 September 2011 - 27 September 2011, http://dx.doi.org/10.1016/S0959-8049(11)71114-5

Alsop K; Fereday S; Meldrum C; deFazio A; Webb P; Birrer MJ; Friedlander M; Fox SB; Bowtell D; Mitchell G, 2011, 'Germ-line BRCA mutations in high-grade ovarian cancer: A case for routine BRCA mutation screening after a diagnosis of invasive ovarian cancer', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.5026

Friedlander M; Stockler MR; King M; Oza AM; Voysey M; Martyn J; Gillies K; Sjoquist KM; Butow P, 2011, 'Measuring subjective improvement as well as objective response to estimate the benefit of palliative chemotherapy in women with platinum-resistant or -refractory ovarian cancer: The symptom benefit study (ANZGOG-0701/GCIG/PoCoG).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.tps241

Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote IB; Rustin GJS; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Macpherson E; Watkins C; Carmichael J; Matulonis U, 2011, 'Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.5003

Harvey S; Milne RL; Birch KE; Weideman P; McLachlan S; Friedlander M; Goldgar D; Hopper JL; Phillips K, 2011, 'Prospective study of breast cancer risk in mutation-negative women from BRCA1 or BRCA2 mutation-positive families in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.1516

Phillips K; Milne RL; Rookus MA; Goldgar D; Friedlander M; McLachlan S; Buys SS; Antoniou AC; Birch KE; Terry MB; Easton D; Weideman P; Daly MB; Andrieu N; John EM; Hooning M; Andrulis IL; Caldes T; Olsson H; Hopper JL, 2011, 'Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers: A combined analysis from the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), the International BRCA1 and BRCA2Carrier Cohort Study (IBCCS), and the Breast Cancer Family Registry (BCFR).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.1500

Stuart GCE; Kitchener H; Bacon M; DuBois A; Friedlander M; Ledermann J; Marth C; Thigpen T; Trimble E, 2011, '2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: Report from the fourth ovarian cancer consensus conference', in International Journal of Gynecological Cancer, pp. 750 - 755, http://dx.doi.org/10.1097/IGC.0b013e31821b2568

Houghton BB; Grimison PS; Toner GC; Chatfield M; Thomson DB; Friedlander M; Gebski V; Rosenthal M; Gurney H; Stockler M, 2011, 'The effect of pulmonary function testing on bleomycin dosing in germ cell tumors', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2011.29.7_suppl.227

Watts KJ; Meiser B; Conlon H; Rovelli S; Tiller K; Zorbas H; Lewis C; Neil G; Friedlander M, 2010, 'Implementation and evaluation of a new specialist breast care nurse role for women with metastatic breast cancer', in Asia-Pacific Journal of Clinical Oncology, Blackwell Publishing Asia, Australia, presented at Clinical Oncological Society of Australia 37th Annual Scientific Meeting, Melbourne, 09 November 2010 - 12 November 2010

Lemech CR; Cosman R; Lee C; Friedlander M; Lewis C; Lynch J; Thomas D; Clingan P; Glasgow A, 2010, 'Cardiac dysfunction in patients receiving trastuzumab for early stage breast cancer in the SESIAHS', in Aisa-Pacific Journal of Clinical Oncology, Sydney Australia, presented at Medical Oncology Group of Australia Annual Scientific Meeting, Sydney Australia, 12 August 2010 - 14 August 2010, http://onlinelibrary.wiley.com/doi/10.1111/j.1743-7563.2010.01301.x/epdf

Lee CK; Guardiola E; Hogberg T; Friedlander M; Bentley J; Denison U; Vergote IB; Pisano C; Parma G; Wimberger P, 2010, 'Development of a nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer based on the CALYPSO trial', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2010.28.15_suppl.5105

Park SB; Lin CS-Y; Krishnan AV; Friedlander M; Lewis C; Kiernan MC, 2010, 'Pathophysiology of paclitaxel-induced neurotoxicity', in Small D (ed.), Australian Neurosciences Society Annual Scientific Meeting 2010, ANS, Sydney, pp. 160 - 160, presented at Australian Neurosciences Society Annual Scientific Meeting 2010, Sydney, 31 January 2010 - 03 February 2010

Webber K; Goldstein D; Bennett BK; Boyle F; De Souza PL; Wilken N; Friedlander M; Lloyd AR, 2010, 'Late fatigue after adjuvant therapy for early breast cancer is largely unrelated to cancer or its treatment: 5 year follow-up of a prospective cohort study', in Asia-Pacific Journal of Clinical Oncology, Blackwell Publishing Asia Pty Ltd, Australia, pp. 53 - 60, presented at ., -

Bennett BK; Goldstein D; De Souza PL; Wilken N; Friedlander M; Hickie IB; Scott E; Rogers N; Lloyd AR, 2010, 'What part does sleep disturbance play in post-cancer fatigue? Findings from a prospective cohort study', in Journal of Clinical Oncology, American Society of Clinical Oncology, United States, pp. 93s

Kiely BE; Jenkins MA; McKinley JM; Friedlander ML; Weideman PC; Milne R; McLachlan S; Hopper JL; Phillips K, 2009, 'Contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, presented at 45th Annual Meeting of the American-Society-of-Clinical-Oncology, FL, Orlando, 29 May 2009 - 02 June 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000276606602105&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Audeh MW; Penson RT; Friedlander M; Powell B; Bell-McGuinn KM; Scott C; Weitzel JN; Carmichael J; Tutt A, 2009, 'Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, presented at 45th Annual Meeting of the American-Society-of-Clinical-Oncology, FL, Orlando, 29 May 2009 - 02 June 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000276606600002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Tutt A; Robson M; Garber JE; Domchek S; Audeh MW; Weitzel JN; Friedlander M; Carmichael J, 2009, 'Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, presented at 45th Annual Meeting of the American-Society-of-Clinical-Oncology, FL, Orlando, 29 May 2009 - 02 June 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000276607000010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Back to profile page